From synovial tissue to peripheral blood: Myeloid related protein 8/14 is a sensitive biomarker for effective treatment in early drug development in patients with rheumatoid arthritis

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Choi, Ivy Y ^a   Gerlag, Danielle M ^a,c   Holzinger, Dirk ^b   Roth, Johannes ^b   Tak, Paul P ^a,c,d  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c GLAXOSMITHKLINE   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIRHEUMATIC AGENT; C REACTIVE PROTEIN; CD68 ANTIGEN; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CLEMASTINE FUMARATE; INFLIXIMAB; MYELOID RELATED PROTEIN 14; MYELOID RELATED PROTEIN 8; PARACETAMOL; PROTEIN; RITUXIMAB; UNCLASSIFIED DRUG; ABC TRANSPORTER; ABCC11 PROTEIN, HUMAN; BIOLOGICAL MARKER; CALGRANULIN B; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BLOOD; BONE MARROW CELL; CELL FUNCTION; CONTROLLED STUDY; DISEASE ACTIVITY SCORE; DISEASE DURATION; DISEASE MARKER; DISEASE PREDISPOSITION; FEMALE; HUMAN; JOINT BIOPSY; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RHEUMATOID ARTHRITIS; SYNOVIUM; ARTHRITIS, RHEUMATOID; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALGRANULIN B; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84940306245     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106253     Document Type: Article

References (16)

1. Gerlag DM, Tak PP (2008) Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials. Best Pract Res Clin Rheumatol 22: 311-323. S1521-6942(08)00014-4 [pii];10.1016/j.berh.2008.02.002 [doi].
2. Haringman JJ, Gerlag DM, Zwinderman AH, Smeets TJ, Kraan MC, et al. (2005) Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 64: 834-838. ard.2004.029751 [pii];10.1136/ard.2004.029751 [doi].
3. Wijbrandts CA, Vergunst CE, Haringman JJ, Gerlag DM, Smeets TJ, et al. (2007) Absence of changes in the number of synovial sublining macrophages after ineffective treatment for rheumatoid arthritis: Implications for use of synovial sublining macrophages as a biomarker. Arthritis Rheum 56: 3869-3871. 10.1002/art.22964 [doi]. (Pubitemid 350100720)
4. Bresnihan B, Pontifex E, Thurlings RM, Vinkenoog M, El-Gabalawy H, et al. (2009) Synovial tissue sublining CD68 expression is a biomarker of therapeutic response in rheumatoid arthritis clinical trials: consistency across centers. J Rheumatol 36: 1800-1802. 36/8/1800 [pii];10.3899/jrheum.090348 [doi].
5. van Kuijk AW, Vergunst CE, Gerlag DM, Bresnihan B, Gomez-Reino JJ, et al. (2010) CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis 69: 2013-2016. ard.2010.131235 [pii];10.1136/ard.2010.131235 [doi].
6. Gerlag D, Tak PP (2005) Synovial biopsy. Best Pract Res Clin Rheumatol 19: 387-400. S1521-6942(05)00006-9 [pii];10.1016/j.berh.2005.01.005 [doi].
7. Frosch M, Strey A, Vogl T, Wulffraat NM, Kuis W, et al. (2000) Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 43: 628-637. 10.1002/1529-0131(200003)43:3<628::AID- ANR20>3.0.CO;2-X [doi]. (Pubitemid 30394955)
8. Choi I, Gerlag DM, Herenius M, Thurlings R, Wijbrandts C, et al. (2013) MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis. Ann Rheum Dis.
9. Wijbrandts CA, Dijkgraaf MG, Kraan MC, Vinkenoog M, Smeets TJ, et al. (2008) The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium. Ann Rheum Dis 67: 1139-1144. ard.2007.080440 [pii];10.1136/ard.2007. 080440 [doi].
10. Wijbrandts CA, van Leuven SI, Boom HD, Gerlag DM, Stroes EG, et al. (2009) Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis. Ann Rheum Dis 68: 1316-1321. ard.2007.086728 [pii];10.1136/ard.2007.086728 [doi].
11. Thurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag DM, et al. (2008) Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis 67: 917-925. ard.2007.080960 [pii];10.1136/ard.2007.080960 [doi].
12. Vergunst CE, Gerlag DM, Dinant H, Schulz L, Vinkenoog M, et al. (2007) Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation. Rheumatology (Oxford) 46: 1773-1778. kem222 [pii];10.1093/rheumatology/kem222 [doi].
13. Vergunst CE, Gerlag DM, Lopatinskaya L, Klareskog L, Smith MD, et al. (2008) Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 58: 1931-1939. 10.1002/art.23591 [doi]. (Pubitemid 351988084)
14. Conaghan PG, Durez P, Alten RE, Burmester GR, Tak PP, et al. (2013) Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial. Ann Rheum Dis 72: 1287-1294. annrheumdis-2012-201611 [pii];10.1136/annrheumdis-2012-201611 [doi].
15. Holzinger D, Frosch M, Kastrup A, Prince FH, Otten MH, et al. (2012) The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis 71: 974-980. annrheumdis-2011-200598 [pii];10.1136/annrheumdis-2011-200598 [doi].
16. Hess A, Axmann R, Rech J, Finzel S, Heindl C, et al. (2011) Blockade of TNF-alpha rapidly inhibits pain responses in the central nervous system. Proc Natl Acad Sci U S A 108: 3731-3736. 1011774108 [pii];10.1073/pnas.1011774108 [doi].